-
Product Insights
Keratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2023
Global Markets Direct’s, ‘Keratoconjunctivitis Sicca (Dry Eye) - Drugs In Development, 2023’, provides an overview of the Keratoconjunctivitis Sicca (Dry Eye) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Keratoconjunctivitis Sicca (Dry Eye), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Keratoconjunctivitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Keratoconjunctivitis - Drugs In Development, 2023’, provides an overview of the Keratoconjunctivitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Keratoconjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – A-197 in Keratoconjunctivitis Sicca (Dry Eye)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - A-197 in Keratoconjunctivitis Sicca (Dry Eye) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. A-197 in Keratoconjunctivitis Sicca (Dry Eye) Drug Details: A-197...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ITI-1001 in Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ITI-1001 in Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ITI-1001 in Glioblastoma Multiforme (GBM) Drug Details: ITI-1001 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RMC-6236 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RMC-6236 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.RMC-6236 in Solid Tumor Drug Details:RMC-6236 is under development for the treatment of...
-
Company Profile
The Estee Lauder Companies Inc – Company Profile
The Estee Lauder Companies Inc (Estee Lauder) is a manufacturer, marketer and distributor of beauty products. The company offers makeup, hair care, fragrance and skin care products. Estee Lauder markets its products under Estee Lauder, Aramis, Origins, Bobbi Brown, Aveda, Clinique, Darphin, Dr. Jart+, Editions de Parfums Frederic Malle, Estée Lauder, and GLAMGLOW brand names. It sells products through specialty multi-brand retailers, department stores, perfumeries, beauty salons and spas, authorized freestanding stores, online retail stores, duty-free shops, and stores on...
Add to Basket -
Company Insights
The Estée Lauder Companies Inc. – Company Overview and Analysis, 2023 Update
Estée Lauder Company Overview Headquartered in New York City, USA, Estée Lauder operates across the cosmetics & toiletries industry. It markets products under various brand names such as Estée Lauder, Aramis, Clinique, Origins, La Mer, Bobbi Brown, Aveda, Donna Karan, Michael Kors, Ermenegildo Zegna, and Tom Ford. The company’s operations are spread across Asia-Pacific, the Middle East, Europe, Africa, and the Americas. The "Estée Lauder - Company Overview and Analysis, 2023 Update" report is based on market analysis and brand...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – A-197
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry A-197 Drug Details A-197 is under development for treatment of dry eye disease and...
-
Product Insights
Keratoconjunctivitis sicca (Dry Eye) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Keratoconjunctivitis sicca (KCS) or dry eye disease (DED) or dry eye syndrome (DES) symptoms include hyperemia, mucoid discharge, ocular irritation, photophobia, and blurry vision. Risk factors include age, wearing contact lenses and low levels of vitamin A. Treatment includes artificial tear substitutes, topical anti-inflammatory agents, secretagogues, and immunosuppressants. The KCS pipeline drugs market research report provides an analysis of the KCS drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The...